217 filings
Page 3 of 11
6-K
t8ptn6u
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
3eumpkl2f87uyil
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
6w98igcdrjog bespr
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
43sqttb
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am
6-K
forsrjnc9b4k
3 Oct 22
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
5:43pm
6-K
l8z 9gr0e
26 Sep 22
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by
7:18am
6-K
hh5ro
12 Sep 22
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
8:17am
6-K
16gsugdroe vc
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
UPLOAD
tezce0710na95
24 Aug 22
Letter from SEC
12:00am
6-K
e1vphb417net3p
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm
CORRESP
v4871st49l ku
19 Aug 22
Correspondence with SEC
12:00am
UPLOAD
ylt3rn21zxmxez4zx
8 Aug 22
Letter from SEC
12:00am
6-K
dt2fg
5 Jul 22
Current report (foreign)
4:15pm
CT ORDER
79rmt33char0di4 yo
10 Jun 22
Confidential treatment order
1:47pm
6-K
us2r wp7zg
2 Jun 22
Mereo Also Updates Capital Allocation and Portfolio Prioritization Plan
9:07am
6-K
xee24
26 May 22
Current report (foreign)
5:11pm
6-K
rcu1xvkg48uxay6
26 May 22
Current report (foreign)
4:11pm
6-K
rw6j6 a3u3
25 May 22
Current report (foreign)
4:11pm
8-A12B/A
dvrtls 6ihqu
17 May 22
Registration of securities on exchange (amended)
8:36am
6-K
mtojlrv6hwd8 k9u
17 May 22
Current report (foreign)
8:26am